Buprenorphine: A Review of its Pharmacological Properties and Therapeutic Efficacy

@article{Heel2012BuprenorphineAR,
  title={Buprenorphine: A Review of its Pharmacological Properties and Therapeutic Efficacy},
  author={Rennie C. Heel and Rex N. Brogden and Trevor M. Speight and Graeme S. Avery},
  journal={Drugs},
  year={2012},
  volume={17},
  pages={81-110}
}
SummarySynopsis: Buprenorphine1, a derivative of the morphine alkaloid thebaine, is a strong analgesic with marked narcotic antagonist activity. In studies in relatively small groups of postoperative patients with moderate to severe pain, one or a few doses of buprenorphine parenterally (by intramuscular or slow intravenous injection) or sublingually2 were at least as effective as standard doses of other strong analgesics such as morphine, pethidine or pentazocine, and buprenorphine was longer… Expand

Paper Mentions

Interventional Clinical Trial
In this case, series, the investigators are testing the hypothesis that sublingual sufentanil (Dsuvia) will improve postoperative pain management in the PACU in ambulatory surgery… Expand
ConditionsAcute Pain
InterventionDrug
Interventional Clinical Trial
To evaluate role of CYP3A in buprenorphine disposition and effect  
ConditionsHealthy
InterventionDrug
Butorphanol: A Review of its Pharmacological Properties and Therapeutic Efficacy
TLDR
Studies in animal models and in a few volunteers have suggested that butorphanol may have a lower dependence liability than narcotic drugs such as morphine or pethidine, and if this is indeed the case it will offer an important advantage over these agents. Expand
Nefopam: A Review of its Pharmacological Properties and Therapeutic Efficacy
TLDR
Nefopam is a non-narcotic analgesic not structurally related to other analgesic drugs, and when appropriate dose ratios were compared in short term studies it was shown to produce analgesia comparable to that with the oral analgesics aspirin, dextropropoxyphene and pentazocine, as well as that with ‘moderate’ doses of parenteral morphine, pethidine and pentacine. Expand
Controlled Drug Administration Studies of High-Dose Buprenorphine in Humans
TLDR
Despite its high-affinity binding and high potency, buprenorphine has a lower efficacy for pain relief and is classified as a partial agonist at µ opiate receptors. Expand
Buprenorphine Pharmacodynamics and Pharmacokinetics
TLDR
This chapter will focus on buprenorphine’s action at mu opioid receptors, and whether the kappa antagonist and/or nociceptin/orphanin partial agonist activity of bup Renorphine produce any effects of clinical relevance, although this has been the focus of some speculation. Expand
A Review of its Use in the Management of Chronic Non-Malignant Pain
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2492
Buprenorphine 5, 10 and 20 μg/h Transdermal Patch
TLDR
Transdermal buprenorphine has generally demonstrated good efficacy and tolerability in clinical trials in chronic non-malignant pain, providing effective background analgesia as part of pain management strategies for patients with osteoarthritis, low back pain and other persistent pain syndromes of at least moderate severity. Expand
Buprenorphine Analgesia in Chronic Pain
TLDR
CYP3A4 inducers, such as ritanovir, amiodarone, ketoconazole, erythromycin, but also grapefruit and star-fruit juice, will hereby elevate the serum buprenorphine level, which was proven by the fact that no differences in pain relief before and after hemodialysis could be observed. Expand
Transdermal Buprenorphine
TLDR
Despite the availability of rescue medication to all patients, those receiving transdermal buprenorphine tended to experience greater pain relief, reduced pain intensity and longer pain-free sleep, and the requirement for rescue medication was reduced from baseline in >50% of patients treated with transderMAL bupenorphine, in two trials. Expand
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
TLDR
Although originally designed as an analgesic, buprenorphine has mainly been used for opioid maintenance therapy and only now is increasingly recognized as an effective analgesic with an improved therapeutic index relative to certain potent opioids. Expand
Transdermal buprenorphine – a critical appraisal of its role in pain management
TLDR
Mounting evidence indicates the appropriateness of Bup TDS in the treatment of diverse acute and chronic pain syndromes which have been less or not responsive to other opioids. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 78 REFERENCES
Pentazocine: A Review of its Pharmacological Properties, Therapeutic Efficacy and Dependence Liability
TLDR
There may be a limit to the analgesia which pentazocine can provide, although such a phenomenon has not been demonstrated in man, and the respiratory depressant effect of pentazOCine in comparison with that of other strong analgesic drugs remains a disputed point. Expand
Butorphanol: A Review of its Pharmacological Properties and Therapeutic Efficacy
TLDR
Studies in animal models and in a few volunteers have suggested that butorphanol may have a lower dependence liability than narcotic drugs such as morphine or pethidine, and if this is indeed the case it will offer an important advantage over these agents. Expand
Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.
TLDR
Buprenorphine has potential for treating narcotic addiction since it is acceptable to addicts, is long-acting, produces a low level of physical dependence such that patients may be easily detoxified, is less toxic than drugs used for maintenance therapy, and blocks the effects of narcotics. Expand
Buprenorphine hydrochloride: Determination of analgesic potency
  • A. Dobkin
  • Medicine
  • Canadian Anaesthetists' Society journal
  • 1977
TLDR
It was concluded that buprenorphine hydrochloride 0.2 to 0.4 mg provided relief of severe pain probably as well as is observed with morphine 10 mg for the average-size patient, but the duration of pain relief with the new compound is substantially longer than with other strong analgesics previously tested. Expand
A comparison of buprenorphine and pethidine for immediate postoperative pain relief by the i.v. route.
TLDR
When the drugs were compared on a "dose per body weight" basis the results supported a ratio of potency in the order of 1 : 200 in favour of buprenorphine, but a similar frequency of nausea was observed with both agents. Expand
Buprenorphine: a new potent long-acting synthetic analgesic. Comparison with morphine.
TLDR
A new thebaine derivative, buprenorphine, 0.6 mg, was compared with morphine 15 mg in a double-blind trial, in patients recovering from elective Caesarean section, with no serious side-effects encountered. Expand
The role of analgesics in respiratory depression: a rabbit model
TLDR
Both pethidine and its metabolites are factors in the persisting depression, while buphrenorphine compared well with pETHidine and fentanyl. Expand
Double-blind evaluation of buprenorphine hydrochloride for post-operative pain
TLDR
Analyses of five parameters showed that the four groups were statistically comparable and that buprenorphine hydrochloride is at least 50 times more potent than morphine sulphate and has a substantially longer duration of analgesic action. Expand
A double blind comparison of buprenorphine and morphine in conscious subjects following administration by the intramuscular route.
TLDR
Buprenorphine produced a more prolonged displacement of the carbon dioxide response curve than morphine, and there was a linear relationship over the dose range 0.15-1.2 mg in terms of respiratory depression. Expand
Use of the chronic spinal dog for the assessment of the abuse potentiality and utility of narcotic analgesics and narcotic antagonists
TLDR
The morphine-dependent chronic spinal dog is useful in identifying partial agonists of the morphine type and yields results comparable with those obtained in man, as well as between their associated agonistic activity. Expand
...
1
2
3
4
5
...